SEC Form 4
------------

Instruction 1(b).

## FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average t	ourden
hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*				ssuer Name <b>and</b> Tic prona Pharma	0	,	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Rickard Ka	<u>thleen A.</u>					<b>7</b> ]	ľ	Director	10% 0			
(Last) 3 MORE LO	(First) NDON RIVER	(Middle)		Date of Earliest Tran 01/2022	saction (Month	/Day/Year)	X	Officer (give title below) Chief Mee	other below lical Officer	(specify )		
(Street)			— 4. If	Amendment, Date	of Original File	d (Month/Day/Year)	6. Indiv Line)	idual or Joint/Grou	p Filing (Check	Applicable		
LONDON	X0	SE1 2RE					X	Form filed by On	e Reporting Per	son		
(City)	(State)	(Zip)	-					Form filed by Mo Person	re than One Re	porting		
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
1 Title of Coord	its (Incota 2)	2 Trans	notion	24 Deemed	2	4 Coourition Acquired (A)	or	E Amount of	6 Ourporchin	7 Noturo		

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)		4. Securities Disposed Of			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150. 4)
Ordinary Shares <sup>(1)</sup>	11/01/2022		F <sup>(2)</sup>		56,264	D	\$1.6 <sup>(3)</sup>	3,119,776	D	
Ordinary Shares <sup>(1)</sup>	11/01/2022		S <sup>(4)</sup>		28,752	D	\$1.639 <sup>(5)</sup>	3,091,024 <sup>(6)</sup>	D	

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

			( 0 / 1					• •							
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)	(Instr.	5. Number of Expiration Date (Month/Day/Year) Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		ate	Amount of Securities		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

## Explanation of Responses:

1. Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

2. Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units.

3. The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on October 31, 2022 divided by eight (8).

4. The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction.

5. The price reported represents a weighted average sale price of the ADSs divided by eight (8). These shares were sold in multiple transactions at prices ranging from \$1.6013 to \$1.6738, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. Consists of (i) 2,141,880 Ordinary Shares underlying RSUs (which are represented by 267,735 ADSs); and (ii) 949,144 Ordinary Shares underlying 118,643 ADSs.

<u>/s/ Claire Poll, Attorney-in-</u> fact for Kathleen A. Rickard <u>11/03/2022</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.